Pancreatic Cancer Clinical Trials

Find Pancreatic Cancer Clinical Trials Near You

Standardised Genetic Profiling of Subjects Belonging to the Italian Multicenter Registry of Prospective Surveillance of Subjects at Genetic Risk of Pancreatic Cancer

Status: Recruiting
Location: See location...
Intervention Type: Genetic
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The goal of the PROPH-ITA Study is to perform genetic testing in family members of pancreatic cancer patients who may have a genetic predisposition. The subjects belong to the Italian Registry of Families At Risk of Pancreatic Cancer (IRFARPC, #NCT04095195). This investigational study will assess the genetic background of subjects with familiarity with pancreatic cancer only. Participants may accept to undergo genetic testing as part of the IRFARPC registry, through a saliva-swab-based 41-gene panel test. Up to 3,000 participants will be enrolled in this study.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Being enrolled on the IRFARPC registry

• Having familiarity for pancreatic cancer (according to the IRFARPC criteria, Capurso et al. Dig Liv Dis, 2020)

• Willingness to participate in saliva-swab-based genetic testing

Locations
Other Locations
Italy
Chirurgia generale e del Pancreas Azienda Ospedaliera Universitaria Integrata
RECRUITING
Verona
Contact Information
Primary
Erica Secchettin, PharmD
familiarita.aisp@gmail.com
0458126254
Backup
AISP Association
aisp.ricerca@gmail.com
340 2713112
Time Frame
Start Date: 2022-12-20
Estimated Completion Date: 2028-12-20
Participants
Target number of participants: 3000
Treatments
Other: Saliva testing swab
Subjects with familiarity with pancreatic cancer enrolled into the IRFARPC registry (NCT04095195) will be submitted to buccal swab for saliva-based genetic testing
Related Therapeutic Areas
Sponsors
Leads: Associazione Italiana per lo Studio del Pancreas
Collaborators: General and Pancreatic Surgery Unit, University of Verona, Genomica srl, Associazione Oltre La Ricerca, Fondazione Valsecchi

This content was sourced from clinicaltrials.gov